Vol 47, No 2 (2016)
Prace poglądowe / Reviews
Published online: 2016-04-01

open access

Page views 176
Article views/downloads 776
Get Citation

Connect on Social Media

Connect on Social Media

Immune checkpoint inhibitors as drugs or drug candidates in neoplastic diseases

Aleksandra Mędra1, Agata Majchrzak1, Piotr Smolewski
DOI: 10.1016/j.achaem.2016.04.008
Acta Haematol Pol 2016;47(2):155-162.

Abstract

Despite of great progress in anti-neoplastic treatment the several solid tumors and hematologic malignancies still remain incurable. Immune system remains under control of several controlling mechanism. Genetic or epigenetic changes in neoplastic cells provide antigen-derived diversity; however, these cells do not initiate immune response. The main mechanism of development of immune resistance by tumor cells seems to be a change in expression of proteins engaged in the immune control point. Immunotherapy with immune checkpoint inhibitors has emerged as promising modality of tumors showing response to several antigens, e.g. anti-CTLA-4 or PD1-PDL1 monoclonal antibodies. In this review we demonstrate the state in the field on this modality of anti-neoplastic treatment.

Article available in PDF format

View PDF (Polish) Download PDF file